GSK (NYSE: GSK), a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her first few years as CEO (see graph below), Walmsley's ambitious restructuring plan has achieved several key goals, including but not limited to higher profitability, dividend payments that align with free cash flows, and a more innovative culture that embraces cutting-edge technologies like artificial intelligence, machine learning, and personalized medicines.

GSK Total Return Level data by YCharts.

Continue reading

Source Fool.com